Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

New calcimimetic agents from ZymoGenetics

Dec. 9, 1996

Etex signs marketing agreement for bone substitute

Dec. 6, 1996

Successful pivotal Mexican trial for oral impotency therapy

Dec. 6, 1996

Houghten's lead CRA safe in diabetics

Dec. 5, 1996

Priority review for Crinone

Dec. 5, 1996

New nonoxynol-9 formulations tested at University of Kentucky

Dec. 4, 1996

Another Barr generic drug cleared by the FDA

Dec. 4, 1996

Alteon amends ACTION II trial

Dec. 4, 1996

Cholesterol-lowering activity reported for Yamanouchi LTD4 antagonist

Dec. 4, 1996

New bisphosphonic acid derivatives from Nippon Chemiphar

Dec. 4, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.